Exact Sciences (NASDAQ:EXAS) Price Target Raised to $96.00

Exact Sciences (NASDAQ:EXAS – Get Rating) had its price objective raised by Benchmark from $81.00 to $96.00 in a research note issued to investors on Thursday, The Fly reports. EXAS has been the subject of a number of other reports. Craig Hallum upgraded shares of Exact Sciences from a hold rating to a buy rating […]

Related Keywords

United States ,Sarah Condella ,Craig Hallum ,Stifel Nicolaus ,Piper Sandler ,James Edward Doyle ,News Ratings For Exact Sciences Daily ,Insider Activity At Exact Sciences ,Sciences Company Profile ,Analyst Recommendations For Exact Sciences ,Ahrens Investment Partners ,Park Place Capital Corp ,Desjardins Global Asset Management Inc ,Securities Exchange Commission ,Ameritas Advisory Services ,Sciences Stock Performance ,Wealth Advisors Inc ,Institutional Trading Of Exact Sciences ,Sciences Corporation ,Jefferies Financial Group ,Exact Sciences ,Get Rating ,Financial Group ,Moderate Buy ,Exchange Commission ,Director James Edward Doyle ,Place Capital Corp ,Advisory Services ,Investment Partners ,Desjardins Global Asset Management ,Global Asset Management ,Recurrence Score Test ,Score Test ,Oncoextra Test ,Exact Sciences Daily ,Nasdaq Exas ,Texas ,Medical ,30063p10 ,Boost Price Target ,Benchmark Co ,